Author

P. Mrozek-Gorska

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Microbiology· 3 Cancer Biology· 1 Cell Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 5 Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Research Focus:cell type annotation· 3 Research Focus:chromatin & epigenetic regulation· 2 Research Focus:differential expression· 2 Research Focus:gene regulatory network inference· 2 Approach:statistical model· 2

Frequent Co-Authors

W. Hammerschmidt· 5 shared D. Pich· 4 shared A. Buschle· 3 shared A. Grundhoff· 1 shared A. Scialdone· 1 shared A. Sugimoto· 1 shared A. Woellmer· 1 shared A.-K. Wirth· 1 shared

Activity by Year

2018-2020 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 22 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersMicrobiology

W. Hammerschmidt

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Inducible transgene expression in PDX models in vivo identifies KLF4 as therapeutic target for B-ALL

W.-H. Liu, P. Mrozek-Gorska, T. Herold, L. Schwarzkopf, D. Pich, K. Völse, A.-K. Wirth, M. C. Melo-Narvaez, M. Carlet, W. Hammerschmidt, I. Jeremias

The paper uses PDX models to show KLF4 re-expression reduces B-ALL leukemia load and sensitizes tumors to chemotherapy, suggesting Azacitidine could regulate KLF4 as a therapeutic option.

bioRxiv · Mar 6, 2020Cancer Biology

The first days in the life of naïve human B-lymphocytes infected with Epstein-Barr virus

D. Pich, P. Mrozek-Gorska, M. Bouvet, A. Sugimoto, E. Akidil, A. Grundhoff, S. Hamperl, P. Ling, W. Hammerschmidt

This study identifies EBNA2 as essential for early EBV infection of naive B-cells, showing it drives activation, proliferation, and prevents cell death, while other latent genes have minimal or no effect during the pre-latent phase.

bioRxiv · Jun 11, 2019Microbiology

Epstein-Barr virus inactivates the transcriptome and disrupts the chromatin architecture of its host cell in the first phase of lytic reactivation

A. Buschle, P. Mrozek-Gorska, S. Krebs, H. Blum, F. M. Cernilogar, G. Schotta, D. Pich, T. Straub, W. Hammerschmidt

This study shows that EBV lytic reactivation causes global chromatin remodeling and transcriptome disruption in host cells before viral DNA replication.

bioRxiv · Mar 20, 2019Cell Biology

Epstein-Barr virus reprograms human B-lymphocytes immediately in the pre-latent phase of infection

P. Mrozek-Gorska, A. Buschle, D. Pich, T. Schwarzmayr, R. Fechtner, A. Scialdone, W. Hammerschmidt

This study shows EBV rapidly reprograms primary human B-lymphocytes transcriptionally within 24 hours of infection, leading to metabolic changes and cell cycle entry by day three.

bioRxiv · Dec 31, 2018Microbiology

BZLF1 interacts with the chromatin remodeler INO80 promoting escape from latent infections with Epstein-Barr virus

M. Schaeffner, P. Mrozek-Gorska, A. Woellmer, T. Tagawa, A. Buschle, N. Krietenstein, C. Lieleg, P. Korber, W. Hammerschmidt

This study identifies BZLF1's role in reactivating Epstein-Barr virus by interacting with the chromatin remodeler INO80 to overcome epigenetic silencing.

bioRxiv · May 8, 2018Microbiology